

In the claims:

1-32. (cancelled)

33. (amended) An antibody or fragment thereof which binds to a B7RP1 polypeptide ~~of amino acid residues 1-322 or 47-322 as set forth in Figure 2A (SEQ ID NO:7) or a mature form thereof.~~

34. (amended) An antibody or fragment thereof which binds to a B7RP1 polypeptide ~~of amino acid residues 1-288 or amino acid residues 19-288, 20-288, 21-288, 22-288, 24-288 or 28-288 as set forth in Figure 3A (SEQ ID NO:12) or a mature form thereof.~~

35. (amended) An antibody or fragment thereof which binds to a B7RP1 polypeptide ~~of amino acid residues 1-302 or amino acid residues 19-302, 20-302, 21-302, 22-302, 24-302 or 28-302 as set forth in Figure 12A (SEQ ID NO:17) or a mature form thereof.~~

36. (amended) An antibody or fragment thereof which specifically binds to a mature form of a B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17) ~~but does not bind to the mature form of a B7RP1 polypeptide of Figure 2A (SEQ ID NO:7).~~

37. (amended) An antibody or fragment thereof which binds to a mature form of a B7RP1 polypeptide as set forth in ~~Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17)~~ and to a mature form of a B7RP1 polypeptide ~~of as set forth in~~ Figure 2A(SEQ ID NO:7).

38. (previously presented) The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a membrane-associated form of a B7RP1 polypeptide of Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

39. (previously presented) The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a soluble form of a B7RP1 polypeptide of Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

40. (previously presented) The antibody or fragment of Claims 34, 35, 36 or 37 which binds to an extracellular domain, or fragment thereof, of a B7RP1 polypeptide of Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

41. (previously presented) The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely blocks the binding of B7RP1 to CRP1.

42. (amended) The antibody or fragment of Claims 34, 35, 36 or 37 which is an agonist antibody that increases B7RP-1 mediated immune costimulatory activity.

43. (amended) The antibody or fragment of Claims 34, 35, 36 or 37 which is an antagonist antibody that decreases B7RP-1 mediated immune costimulatory activity.

44. (amended) The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely inhibits B7RP-1 mediated immune costimulatory activity.

45. (previously presented) An antibody or fragment thereof which binds to a polypeptide encoded by the nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6).

46. (amended) An antibody or fragment thereof which binds to a polypeptide encoded by the nucleotide sequence as set forth in or Figure 3A (SEQ ID NO: 11) or Figure 12A (SEQ ID NO: 16).

47. (amended) The An antibody or fragment of Claim 45 which binds to a soluble form of B7RP1, wherein B7RP1 is encoded by the nucleic acid of Figure 3A (SEQ ID NO:11) or Figure 12A (SEQ ID NO:16).

48. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a monoclonal antibody.

49. **(previously presented)** The antibody of Claims 34, 35, 36 or 37 which is a chimeric antibody.

50. **(previously presented)** The antibody of Claims 34, 35, 36 or 37 which is a single chain antibody.

51. **(previously presented)** The antibody of Claims 34, 35, 36 or 37 which is a bispecific antibody.

52. **(previously presented)** The antibody of Claims 34, 35, 36 or 37 which is a CDR-grafted or humanized antibody.

53. **(previously presented)** The antibody of Claims 34, 35, 36 or 37 which is a human antibody.

54. **(previously presented)** A pharmaceutical composition comprising the antibody of Claims 34, 35, 36 or 37 and a carrier, diluent, and/or excipient.